BRANFORD, Conn.–(BUSINESS WIRE)–Feb. 18, 2025– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and several distinguished researchers will be presenting new research and applications at the 2025 Advances in Genome Biology and Technology (AGBT) General Meeting February 23-26th. Quantum-Si, the pioneer in Next-Generation Protein Sequencing (NGPS™) will feature groundbreaking research […]

BRANFORD, Conn.–(BUSINESS WIRE)–Feb. 13, 2025– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and several distinguished researchers will highlight advances in Next-Generation Protein Sequencing™ (NGPS™) at the US Human Proteome Organization’s 2025 conference in Philadelphia, Pennsylvania through a panel discussion and multiple poster presentations. Sponsored Panel Discussion: Breaking Boundaries in […]

BRANFORD, Conn.–(BUSINESS WIRE)–Feb. 12, 2025– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 3, 2025. Jeff Hawkins, President and Chief Executive Officer, and Jeff Keyes, Chief Financial Officer, will host a […]

BRANFORD, Conn.–(BUSINESS WIRE)–Feb. 11, 2025– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces a newly released preprint from researchers at Northwestern University, titled “Next-Generation Protein Sequencing and individual ion mass spectrometry enable complementary analysis of interleukin-6.” The publication demonstrates the power of combining two cutting-edge technologies, Quantum-Si’s Next-Generation Protein […]

BRANFORD, Conn.–(BUSINESS WIRE)–Feb. 4, 2025– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the formation of its Scientific Advisory Board. Comprised of distinguished experts in proteomics, genomics, bioinformatics, chemistry, and engineering, the board will play a critical role in shaping Quantum-Si’s scientific and development strategy, identifying emerging trends and […]

BRANFORD, Conn.–(BUSINESS WIRE)–Jan. 20, 2025– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces its participation in the upcoming Festival of Genomics UK, taking place on January 29–30, 2025, at ExCeL London. As part of the event, Richard Broadhead, Ph.D., will deliver a presentation highlighting the latest innovations in Next-Generation […]

BRANFORD, Conn.–(BUSINESS WIRE)–Jan. 17, 2025– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 44,893 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 […]

BRANFORD, Conn.–(BUSINESS WIRE)–Jan. 13, 2025– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the launch of Platinum® Pro, its latest benchtop sequencer that sets a new standard in protein analysis. Designed to redefine efficiency and versatility in proteomics research, Platinum Pro is now available for ordering. This press release […]

BRANFORD, Conn.–(BUSINESS WIRE)–Jan. 8, 2025– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, announces the release of its latest preprint titled “Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis, and Tracking.” This study highlights the potential of integrating Quantum-Si’s benchtop Platinum® instrument with an innovative protein barcoding […]

BRANFORD, Conn.–(BUSINESS WIRE)–Jan. 3, 2025– Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 15,625,000 shares of common stock at a purchase price of $3.20 per share, pursuant to a registered […]